ArticleLeukemia2023
Impact of pre-transplant induction and consolidation cycles on AML allogeneic transplant outcomes: a CIBMTR analysis in 3113 AML patients.
Erratum issuedOpen access · greenAbstract read
In one paragraph
Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: a study from the ALWP/EBMT.Bone marrow transplantation · 2026Article
- Optimizing treatment selection and timing of allogeneic haematopoietic stem cell transplantation in acute myeloid leukaemia with concurrent feline McDonough sarcoma (FMS)-like tyrosine kinase 3 internal tandem duplication, nucleophosmin 1 and deoxyribonucleic acid (DNA) methyltransferase 3 alpha mutations.British journal of haematology · 2026Article
- The impact of pretransplant consolidation chemotherapy on clinical outcomes in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a single-center retrospective study.Frontiers in oncology · 2026Article
- Fludarabine melphalan reduced intensity conditioning vs radiation-based myeloablative conditioning in patients undergoing allogeneic transplantation for acute myeloid leukemia with measurable residual disease.Bone marrow transplantation · 2025Article
- Retrospective Analysis of R-COMP Therapy in Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Assessing the Impact of Sample Selection Bias.Journal of clinical medicine · 2025Article
- Transplant or no transplant forOncotarget · 2024Article
- Review
- Allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia not in remission.Leukemia · 2024Article
- Genetic features and outcomes of allogeneic transplantation in patients with WT1-mutated myeloid neoplasms.Blood advances · 2024Article
- Survival after allogeneic transplantation according to pretransplant minimal residual disease and conditioning intensity in patients with acute myeloid leukemia.Frontiers in oncology · 2024Article
- Understanding differential technologies for detection of MRD and how to incorporate into clinical practice.Hematology. American Society of Hematology. Education Program · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
52 authors at 20 institutions in 6 countries.
Michael BoyiadzisUniversity of Pittsburgh, Pittsburgh, PA, USA.
Mei-Jie ZhangCIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Karen ChenCIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Hisham Abdel-AzimLoma Linda University School of Medicine, Cancer Center, Children Hospital and Medical Center, Loma Linda, CA, USA.
Muhammad Bilal AbidDivisions of Hematology/Oncology & Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Mahmoud AljurfDepartment of Oncology, King Faisal Specialist Hospital Center & Research, Riyadh, Saudi Arabia.
Ulrike BacherDepartment of Hematology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Talha BadarDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0003-1548-918X
Sherif M BadawyDivision of Hematology, Oncology and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Minoo BattiwallaSarah Cannon Blood Cancer Network, Nashville, TN, USA.
Nelli BejanyanDepartment of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, FL, USA.ORCID 0000-0003-0194-7338
Vijaya Raj BhattThe Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USA.ORCID 0000-0003-2513-0533
Valerie I BrownDivision of Pediatric Oncology/Hematology, Department of Pediatrics, Penn State Hershey Children's Hospital and College of Medicine, Hershey, PA, USA.ORCID 0000-0002-1186-2138
Paul CastilloUF Health Shands Children's Hospital, Gainesville, FL, USA.ORCID 0000-0002-2813-1729
Jan CernyDivision of Hematology/Oncology, Department of Medicine, University of Massachusetts Medical Center, Worcester, MA, USA.ORCID 0000-0002-6602-5505
Edward A CopelanDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Charles CraddockQueen Elizabeth Hospital, Birmingham, UK.ORCID 0000-0001-5041-6678
Bhagirathbhai DholariaVanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-2371-3655
Miguel Angel Diaz PerezDepartment of Hematology/Oncology, Hospital Infantil Universitario Niño Jesus, Madrid, Spain.
Christen L EbensDivision of Blood and Marrow Transplant & Cellular Therapy, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA.
Robert Peter GaleHaematology Centre, Department of Immunology and Inflammation, Imperial College London, London, UK.ORCID 0000-0002-9156-1676
Siddhartha GangulyHouston Methodist Hospital and Cancer Center, Houston, TX, USA.
Lohith GowdaYale Cancer Center and Yale School of Medicine, New Haven, CT, USA.
Michael R GrunwaldDepartment of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, NC, USA.
Shahrukh HashmiDepartment of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Gerhard C HildebrandtUniversity of Missouri, Ellis Fischel Cancer Center, Columbia, MO, USA.ORCID 0000-0003-0478-3340
Madiha IqbalDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA.
Omer JamyUniversity of Alabama at Birmingham, Birmingham, AL, USA.
Mohamed A Kharfan-DabajaDivision of Hematology-Oncology, Blood and Marrow Transplantation Program, Mayo Clinic, Jacksonville, FL, USA.ORCID 0000-0001-7394-5185
Nandita KheraDepartment of Hematology/Oncology, Mayo Clinic, Phoenix, AZ, USA.
Hillard M LazarusUniversity Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.ORCID 0000-0002-1159-5607
Richard LinMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-0834-7880
Dipenkumar ModiDivision of Oncology, Karmanos Cancer Center/Wayne State University, Detroit, MI, USA.ORCID 0000-0001-6525-8844
Sunita NathanSection of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, IL, USA.ORCID 0000-0001-7920-4265
Taiga NishihoriDepartment of Blood & Marrow Transplant and Cellular Immunotherapy (BMT CI), Moffitt Cancer Center, Tampa, FL, USA.ORCID 0000-0002-2621-7924
Sagar S PatelTransplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.ORCID 0000-0001-9949-3615
Attaphol PawarodeBlood and Marrow Transplantation Program, Division of Hematology/Oncology, Department of Internal Medicine, The University of Michigan Medical School, Ann Arbor, MI, USA.
Wael SaberCIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Akshay SharmaDepartment of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN, USA.ORCID 0000-0003-3281-2081
Melhem SolhThe Blood and Marrow Transplant Group of Georgia, Northside Hospital, Atlanta, GA, USA.ORCID 0000-0003-3766-5623
John L WagnerDepartment of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, USA.
Trent WangDivision of Transplantation and Cellular Therapy, University of Miami, Miami, FL, USA.ORCID 0000-0001-5685-7204
Kirsten M WilliamsChildren's Healthcare of Atlanta, Emory University, Atlanta, GA, USA.
Lena E WinestoneDivision of Allergy, Immunology, and Blood & Marrow Transplant, University of California San Francisco Benioff Children's Hospitals, San Francisco, CA, USA.ORCID 0000-0001-9982-1594
Baldeep WirkBone Marrow Transplant Program, Penn State Cancer Institute, Hershey, PA, USA.ORCID 0000-0002-2804-2531
Amer ZeidanBridgeport Hospital, Yale University School of Medicine, New Haven, CT, USA.
Christopher S HouriganLaboratory of Myeloid Malignancies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID 0000-0002-6189-8067
Mark LitzowDivision of Hematology and Transplant Center, Mayo Clinic Rochester, Rochester, MN, USA.ORCID 0000-0002-9816-6302
Partow KebriaeiDepartment of Stem Cell Transplantation, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.ORCID 0000-0002-8607-9404
Marcos de LimaOhio State University, Columbus, OH, USA.
Kristin PageCIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA.
Daniel J WeisdorfDivision of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN, USA. weisd001@umn.edu.ORCID 0000-0001-8078-8579
Medical College of Wisconsin · USMayo Clinic in Florida · USLevine Cancer Institute · USMoffitt Cancer Center · USPenn State Milton S. Hershey Medical Center · USUniversity of Minnesota · USBridgeport Hospital · USEmory University · USHospital Infantil Universitario Niño Jesús · ESHouston Methodist · USImperial College London · GBKing Faisal Specialist Hospital & Research Centre · SALoma Linda University Medical Center · USMayo Clinic in Arizona · USMemorial Sloan Kettering Cancer Center · USNational Institutes of Health · USNorthside Hospital · USNorthwestern University · USQueen Elizabeth Hospital Birmingham · GBRush University Medical Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MWomen's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3MData Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2MYale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MDetection, prevention and treatment of acute myeloid leukemia (AML) relapse.ZIAHL006163 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI HOURIGAN, CHRISTOPHER · 2013 to 2023
$21.0MNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA015083NCI NIH HHS U24 CA076518
Abstract
We investigated the impact of the number of induction/consolidation cycles on outcomes of 3113 adult AML patients who received allogeneic hematopoietic cell transplantation (allo-HCT) between 2008 and 2019. Patients received allo-HCT using myeloablative (MAC) or reduced-intensity (RIC) conditioning in first complete remission (CR) or with primary induction failure (PIF). Patients who received MAC allo-HCT in CR after 1 induction cycle had 1.3-fold better overall survival (OS) than 2 cycles to CR and 1.47-fold better than ≥3 cycles. OS after CR in 2 or ≥3 cycles was similar. Relapse risk was 1.65-fold greater in patients receiving ≥3 cycles to achieve CR. After RIC allo-HCT, the number of induction cycles to CR did not affect OS. Compared to CR in 1 cycle, relapse risk was 1.24-1.41-fold greater in patients receiving 2 or ≥3 cycles. For patients receiving only 1 cycle to CR, consolidation therapy prior to MAC allo-HCT was associated with improved OS vs. no consolidation therapy. Detectable MRD at the time of MAC allo-HCT did not impact outcomes while detectable MRD preceding RIC allo-HCT was associated with an increased risk of relapse. For allo-HCT in PIF, OS was significantly worse than allo-HCT in CR after 1-3 cycles.
Indexed as
Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteAdultHumansNeoplasm Recurrence, LocalRetrospective StudiesTransplantation ConditioningTransplantation, Homologous
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.